FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to new compounds of the following general formula [1a], wherein R1 represents (1) a hydrogen atom, (2) C1-C6alkyl group, (3) C2-C6alkenyl group, (4) C2-C6alkynyl group, (5) C1-C6alkoxygroup, (6) hydroxyC1-C6alkyl group, (7) C1-C6alkoxy(C1-C6)alkyl group, (8) -CONR11R12, wherein R11 and R12 are identical or different, and each represents a hydrogen atom or C1-C6alkyl group, (9) phenyl group or (10) a five-member heteroaryl group which contains at least one heteroatom specified in a group consisting of a nitrogen atom and oxygen atom, and which may be substituted by C1-C6alkyl group； R2 represents (1) a halogen atom, (2) C1-C6alkyl group, (3) hydroxy group or (4) C1-C6alkoxy group； p is equal to 0, 1, 2 or 3； X represents a carbon atom or nitrogen atom； m1 is equal to 0, 1 or 2； m2 is equal to 0 or 1； the spiro ring AB may be substituted by 1-5 identical or different, specified in a group consisting of (1) hydroxy group, (2) C1-C6alkyl group, (3) C1-C6alkoxygroup and (4) oxo group； n1 is equal to 0, 1, 2, 3 or 4； n2 is equal to 1, 2, 3 or 4； n3 is equal to 0, 1 or 2, provided n2+n3 is equal to 2, 3 or 4； and a bond presented by the symbol means a single bond or a double bond, provided the three adjoining carbon atoms forms no allene bond presented by formula: C=C=C, or a pharmaceutically acceptable salt thereof.EFFECT: invention refers to a pharmaceutical composition possessing GPR40 agonist activity, to a GPR40 agonist drugs； to a hypoglycemic agent stimulating insulin secretion on the basis of the above compounds.45 cl, 42 tbl, 120 exИзобретение относится к новым соединениям следующей общей формулы [Ia], в которой R1 представляет собой (1) атом водорода, (2) C1-C6алкильную группу, (3) C2-C6алкенильную группу, (4) C2-C6алкинильную группу, (5) C1-C6алкоксигруппу, (6) гидроксиC1-C6алкильную группу, (7) C1-C6алкокси(C1-C6)алкильную группу, (8) -CONR11R12, в которой R11 и R12 являются одинаковыми или различны
